Actively Recruiting
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
Led by Du Juan · Updated on 2024-07-10
40
Participants Needed
2
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.
CONDITIONS
Official Title
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed pancreatic cancer
- ECOG performance status of 0 to 2
- Radiographically diagnosed locally advanced pancreatic cancer per NCCN guidelines
- No prior anti-tumor therapy
- Able and willing to provide written informed consent
You will not qualify if you...
- Prior anti-tumor therapy of any kind
- Severe infection greater than NCI CTC grade 2
- Autoimmune disease or immune deficiency treated with immunosuppressive drugs
- Bleeding tendency
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
FirstNanjingMU
Nanjing, Jiangsu, China, 025
Not Yet Recruiting
2
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China, 025
Actively Recruiting
Research Team
J
Juan Du, M.D. Ph.D
CONTACT
J
Juan Du
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here